Johnson & Johnson

YTD

ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.

CEO

Joaquin Duato

CEOJoaquin Duato

Employees

138,100

Employees138,100

Headquarters

New Brunswick, New Jersey

HeadquartersNew Brunswick, New Jersey

Founded

1887

Founded1887

Employees

138,100

Employees138,100

JNJ Key Statistics

Market cap

374.84B

Market cap374.84B

Price-Earnings ratio

17.26

Price-Earnings ratio17.26

Dividend yield

3.23%

Dividend yield3.23%

Average volume

7.55M

Average volume7.55M

High today

$156.76

High today$156.76

Low today

$154.21

Low today$154.21

Open price

$154.40

Open price$154.40

Volume

6.44M

Volume6.44M

52 Week high

$169.99

52 Week high$169.99

52 Week low

$140.68

52 Week low$140.68

JNJ News

Simply Wall St 14h

Johnson & Johnson Submits sNDA For Schizophrenia Drug CAPLYTA® To FDA

submitted a supplemental New Drug Application for CAPLYTA®, aiming to prevent schizophrenia relapse, marking a significant step in expanding its mental health p...

TipRanks 19h

Johnson & Johnson submits sNDA to U.S FDA for CAPLYTA

Johnson & Johnson announced the submission of a supplemental New Drug Application, sNDA, to the U.S. Food and Drug Administration, FDA, based upon long-term dat...

TipRanks 1d

Nanobiotix announces regulatory harmonization, new patent for JNJ-1900

Nanobiotix (NBTX) announced two developments related to radioenhancer JNJ-1900, which is licensed by Janssen Pharmaceutica, a Johnson & Johnson (JNJ) company. H...

Analyst ratings

56%

of 25 ratings

Buy

44%

Hold

56%

Sell

More JNJ News

TipRanks 2d

Balanced Outlook on Johnson & Johnson: MedTech Growth vs. Pharmaceutical Challenges

Analyst Larry Biegelsen from Wells Fargo maintained a Hold rating on Johnson & Johnson and keeping the price target at $170.00. Don’t Miss TipRanks’ Half-Year...

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.